Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com

Ref. No: **ADL/SE/2G/2010/147**
Date : 4th November, 2010

To,
Department of Corporate Services
Bombay Stock Exchange, Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

BSE CODE –524348
Dear Sir,

To,
National Stock Exchange of
India Limited
"Exchange Plaza",
Bandra - Kurla Complex,
Bandra (E), Mumbai – 400 051.

NSE CODE:AARTIDRUGS

Ref : Compliance of Clause 22 and Clause 36 of the Listing Agreement
Sub: Intimation of proposed issue of convertible warrants on preferential basis.

It is hereby informed to the Exchange that at the meeting of the Board of Directors of the Company, held on 4th November, 2010, the following decision has been taken subject to the approval of the Company at its Extra-ordinary General Meeting to be held on 2nd December, 2010.

Pursuant to the provisions of Section 81(1A) and all other applicable provisions of the Companies Act, 1956 (including any statutory modifications or re-enactment thereof, for the time being in force) and pursuant to the provisions of Chapter VII of the SEBI [(Issue of Capital and Disclosure Requirements) Regulations, 2009], the Company shall issue not exceeding 650000 convertible warrants, on preferential basis, to the Promoters, Promoter Group/ Companies and others, subject to the shareholder's approval, as aforesaid.

Each of the said warrants would entitle the holder thereof to apply for and obtain allotment of one Equity share of Rs. 10/- each thereof on a future date not exceeding 18 months from the date of allotment of warrant as per the Chapter VII of the SEBI [(Issue of Capital and Disclosure Requirements) Regulations, 2009] at an issue price of Rs. 141.25 ps per share. The issue price for the warrants is fixed at 25% of the issue price of the resulting shares upon conversion.

The "Relevant Date" for the purpose of determining the said issue price for the Preferential Issue of the warrants and resultant shares as aforesaid is 2nd November, 2010 i.e. 30 days prior to the date of the Extra-ordinary General Meeting to be held on 2nd December, 2010 at which the said preferential issue will be considered for approval in terms of Chapter VII of the SEBI [(Issue of Capital and Disclosure Requirements) Regulations, 2009].

Please take the above on record and do the needful.

Thanking you,

Yours faithfully,
For **AARTI DRUGS LIMITED**

HARSHIT M. SAVLA
JT. MANAGING DIRECTOR